Cilomilast has not yet been approved in the US, EU or Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (view UK and US information for Healthcare Professionals).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Cilomilast studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
CIL103657 III A Randomized, 24 week, Double blind, Placebo controlled, Parallel group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
SB207499/039 III A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/040 III A Multicentre, Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral SB-207499 (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/041 III A Multicenter Open-label Extension Study to Evaluate the Safety, Tolerability and Efficacy of Oral Cilomilast (15 mg twice daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD)
SB207499/042 III A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/076 III A 12-week, Multicentre, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of SB207499 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
SB207499/091 III A Randomized, 24-Week, Double-blind, Placebo-controlled, Parallel-Group Study Followed by a 2-Week, Randomized, Double-blind, Run-out Phase to Evaluate the Efficacy, Safety, Tolerability and Discontinuation of SB207499 (15mg Twice Daily) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/110 III A 12-week, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Anti-inflammatory Activity of Cilomilast 15 mg Twice Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)
SB207499/111 III A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of Cilomilast (15 mg Twice Daily) on Trapped Gas Volume in Patients With Chronic Obstructive Pulmonary Disease
SB207499/121 III A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB-207499/125 III A Randomized, 12-Week, Double-blind, Placebo-controlled, Parallel-group Pilot Study to Evaluate the Safety and Additional Efficacy of Adding Cilomilast 15 mg Twice Daily to Treatment with ADVAIR 250/50 Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/156 III A Randomized, 24-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Cilomilast (15mg BID) in Patients with Chronic Obstructive Pulmonary Disease (COPD).
SB207499/157 III A Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Oral Cilomilast (15 mg bd) When Given as Maintenance Treatment for 12 Months to Subjects with Chronic Obstructive Pulmonary Disease (COPD)
SB207499/168 III A Randomized, 12-week, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Tolerability of Cilomilast 15mg Twice Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD)
SB207499/180 III An 18-week randomized, double-blind, placebo-controlled, multicenter study designed to compare treatment with cilomilast to that with placebo for changes in ventilatory mechanics and function (both at rest and during exercise), as well as related exertional dyspnea and exercise performance, in hyperinflated patients with stable COPD
SB207499/181 III A 13-week randomised, double-blind, parallel group, mulitcentre study to compare the bronchial antiinflammatory activity of oral cilomilast (15 mg bd) with placebo twice daily in subjects with Chronic Obstructive Pulmonary Disease (COPD)